Publicacións en colaboración con investigadores/as de Complejo Hospitalario de Toledo (25)

2023

  1. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

  2. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Expanding the genetic spectrum of TUBB1-related thrombocytopenia

    Blood Advances, Vol. 5, Núm. 24, pp. 5453-5467

  4. Management of acquired hemophilia A: results from the Spanish registry

    Blood Advances, Vol. 5, Núm. 19, pp. 3821-3829

  5. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

2020

  1. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

    Experimental Hematology and Oncology

  2. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort

    Thrombosis and Haemostasis, Vol. 120, Núm. 3, pp. 437-448

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

    Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

  3. Unraveling the effect of silent, intronic and missense mutations on VWF splicing: Contribution of next generation sequencing in the study of mRNA

    Haematologica, Vol. 104, Núm. 3, pp. 587-598

2018

  1. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

    Blood Cancer Journal, Vol. 8, Núm. 10

  2. Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders

    Haematologica, Vol. 103, Núm. 1, pp. 148-162

  3. Role of multimeric analysis of von willebrand factor (VWF) in von willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients

    Haematologica, Vol. 102, Núm. 12, pp. 2005-2014

2016

  1. Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50

  2. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 532-540

2015

  1. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

    Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002